Query author contributions in Reactome
Reactome depends on collaboration between our curation team and outside experts to
assemble and peer-review its pathway modules. The integration of ORCID within Reactome
enables us to meet a key challenge with authoring, curating and reviewing biological
information by incentivizing and crediting the external experts that contribute their
expertise and time to the Reactome curation process. More information is available at
ORCID and Reactome.
If you have an ORCID ID that is not listed on this page, please
forward this information to us and we will update your Reactome pathway records.
Details on Person Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns
| Class:Id | LiteratureReference:9699359 |
|---|
| _displayName | Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns |
|---|
| _timestamp | 2020-09-14 12:19:48 |
|---|
| author | [Person:9699367] Moore, A S
[Person:9699368] Faisal, A
[Person:9699358] Gonzalez de Castro, D
[Person:9699372] Bavetsias, V
[Person:9013784] Sun, C
[Person:9699374] Atrash, B
[Person:9699361] Valenti, M
[Person:9699365] de Haven Brandon, A
[Person:9699370] Avery, S
[Person:9699375] Mair, D
[Person:9699362] Mirabella, F
[Person:9699364] Swansbury, J
[Person:9699371] Pearson, A D J
[Person:9699369] Workman, P
[Person:9699373] Blagg, J
[Person:9699357] Raynaud, F I
[Person:9699360] Eccles, S A
[Person:9699363] Linardopoulos, S |
|---|
| created | [InstanceEdit:9699366] Rothfels, Karen, 2020-09-14 |
|---|
| journal | Leukemia |
|---|
| pages | 1462-70 |
|---|
| pubMedIdentifier | 22354205 |
|---|
| title | Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns |
|---|
| volume | 26 |
|---|
| year | 2012 |
|---|
| (literatureReference) | [Reaction:9702510] FLT mutants bind type II TKIs [Homo sapiens]
[FailedReaction:9702618] quizartinib-resistant FLT3 mutants don't bind quizartinib [Homo sapiens]
[FailedReaction:9702623] sorafenib-resistant FLT3 mutants don't bind sorafenib [Homo sapiens]
[DefinedSet:9699523] tandutinib-resistant FLT3 mutants [plasma membrane] [Homo sapiens]
[DefinedSet:9699531] quizartinib-sensitive FLT3 mutants [plasma membrane] [Homo sapiens]
[DefinedSet:9699540] tandutinib-sensitive FLT3 mutants [plasma membrane] [Homo sapiens] |
|---|
|
[Change default viewing format]
|
No pathways have been reviewed or authored by Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns (9699359)
